John Leonard, Intellia CEO
Alongside promising first HAE data, Intellia posts readout in Regeneron-partnered ATTR program
In August, Alnylam touted a Phase III success for transthyretin amyloidosis, or ATTR for short, with cardiomyopathy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
